Möchten Sie immer auf dem neuesten Stand bleiben?

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Infectious Disease Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering. The infectious disease clinical...

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Mental Health Clinical Trials Market Report 2026" has been added to ResearchAndMarkets.com's offering. The mental health clinical trials market...

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Clinical Trial Software Market Report 2026" has been added to ResearchAndMarkets.com's offering. The clinical trial software market is poised for...

Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "AI-Based Clinical Trial Solution Providers Market Report 2026" has been added to ResearchAndMarkets.com's offering. The AI-based clinical trial...

VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN) (OTC Pink: HYTNF) (FSE: 85W0) ("HYTN" or the "Company") announces that its Board of Directors has...

Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the...

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the...

Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication ...

HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and...

Addition of globally recognized leaders in translational science and clinical development as the Company advances its pipeline towards key inflection points NEW YORK and TORONTO, April 23, 2026 ...